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AbstrAct
background WHO's 2020 milestones for Chagas disease 
include having all endemic Latin American countries 
certified with no intradomiciliary Trypanosoma cruzi 
transmission, and infected patients under care. Evaluating 
the variation in historical exposure to infection is crucial for 
assessing progress and for understanding the priorities to 
achieve these milestones.
Methods Focusing on Colombia, all the available age-
structured serological surveys (undertaken between 
1995 and 2014) were searched and compiled. A total 
of 109 serosurveys were found, comprising 83 742 
individuals from rural (indigenous and non-indigenous) 
and urban settings in 14 (out of 32) administrative units 
(departments). Estimates of the force-of-infection (FoI) 
were obtained by fitting and comparing three catalytic 
models using Bayesian methods to reconstruct temporal 
and spatial patterns over the course of three decades 
(between 1984 and 2014).
results Significant downward changes in the FoI 
were identified over the course of the three decades, 
and in some specific locations the predicted current 
seroprevalence in children aged 0–5 years is <1%. 
However, pronounced heterogeneity exists within 
departments, especially between indigenous, rural and 
urban settings, with the former exhibiting the highest 
FoI (up to 66 new infections/1000 people susceptible/
year). The FoI in most of the indigenous settings remain 
unchanged during the three decades investigated. Current 
prevalence in adults in these 15 departments varies 
between 10% and 90% depending on the dynamics of 
historical exposure.
conclusions Assessing progress towards the control 
of Chagas disease requires quantifying the impact of 
historical exposure on current age-specific prevalence 
at subnational level. In Colombia, despite the evident 
progress, there is a marked heterogeneity indicating 
that in some areas the vector control interventions have 
not been effective, hindering the possibility of achieving 
interruption by 2020. A substantial burden of chronic 
cases remains even in locations where serological criteria 
for transmission interruption may have been achieved, 
therefore still demanding diagnosis and treatment 
interventions.
IntroductIon
Chagas disease is of great public health 
concern in the American continent, where 
an estimated 5.7 million people are affected,1 
and 271 000–1 054 000 disability-adjusted life 
years are lost mainly due to heart complica-
tions and premature deaths.2 3 In 2012, WHO 
set milestones for Chagas disease, namely, 
achieving interruption of transmission via 
blood transfusion by 2015 and interruption of 
intradomiciliary vectorborne transmission by 
2020,4 as well as having all infected/ill people 
under care.5 In addition to the verification of 
absence of triatomines in a specific area with 
a well-conducted surveillance programme, 
reaching a seroprevalence <2% among chil-
dren aged under 5 years has been set as an 
operational threshold to indicate transmis-
sion interruption.6 However challenging, 
quantifying whether endemic countries are 
on track to achieve the 2020 goals is, there-
fore, timely and imperative.
Control strategies for Chagas disease 
have mostly focused on insecticide-spraying 
campaigns against triatomine vectors and 
screening of transfusion units in blood 
banks. Countries of the Southern Cone have 
achieved a substantial decrease in prevalence; 
Brazil, Chile and Uruguay have successfully 
interrupted transmission by Triatoma infes-
tans, the principal vector in the subregion, as 
defined by the Pan American Health Orga-
nization. The Andean Countries Initiative 
(Iniciativa de Países Andinos (IPA)) started in 
1997 in Colombia, Ecuador, Peru and Vene-
zuela. In Colombia, IPA aimed to control 
intradomiciliary transmission by Rhodnius 
prolixus and introduced mandatory screening 
of blood banks. Due to greater vector diversity 
in the Andean subregion and administrative 
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difficulties in implementing vector control, progress has 
been slow, and interruption of vectorial transmission has 
yet to be achieved or demonstrated.7 Accurate descrip-
tion of temporal and spatial patterns of incidence and 
prevalence is a prerequisite for the design of optimal 
strategies for interruption of transmission, diagnosis of 
prevalent cases and treatment as well as for monitoring 
and evaluation of progress made towards national and 
regional goals.
In Colombia, an estimated 437 960 people are infected 
and 131 388 live with chronic cardiomyopathy,1 and <1% 
have access to diagnosis and aetiological treatment.8 
Therefore, even if vectorial transmission were inter-
rupted, past exposure must be assessed to design and 
implement appropriate diagnostic and treatment strat-
egies. Taking Colombia as a case study, this paper aims 
to characterise past and present epidemiological trends 
of Chagas disease based on historical seroprevalence 
data. The key parameter of interest in this study is the 
‘per susceptible’ (at-risk) rate of infection acquisition, 
more commonly referred to as the ‘force-of-infection’ 
(FoI). A better understanding of FoI patterns will enable 
identification of (i) active transmission areas, (ii) areas 
where past control strategies have succeeded (or failed) 
and (iii) local variations in disease burden. Using data 
compiled on an unprecedented scale, we reconstruct 
and identify trends in spatial and temporal transmission 
of Chagas disease in Colombia. The paper aims to ascer-
tain heterogeneity in incidence and prevalence and to 
present a quantitative framework to address the question 
of whether Colombia in particular is on track to achieve 
the 2020 goals for Chagas disease set by WHO. We argue 
that, more generally, our approach could be applied to 
the analysis of seroprevalence data from other countries 
in Latin America to assist endemic countries’ efforts in 
assessing Chagas disease control progress and needs in 
the region.
Methods
survey selection and data extraction
PubMed, Web of Knowledge and the Latin American 
Index (Literatura Latinoamericana de Información en 
Ciencias de la Salud, in Spanish) databases were searched 
for the period 1995–2014, with no year or language 
restrictions. Non-published data and grey literature 
including personal collections, research degree theses 
filed in Colombian universities and unpublished reports 
from control programmes at the National Health Insti-
tute and Ministry of Health in Colombia were also scru-
tinised.
Surveys had to meet all of the following inclusion 
criteria: (i) be population based (not hospital based), 
(ii) specify individuals’ age or age group, (iii) indicate 
diagnostic test(s) used and (iv) identify location and 
date of sample collection. When detailed information 
was not available, corresponding authors were contacted. 
If the reports contained several surveys conducted in 
different locations or years, each survey was extracted 
as a unit. Settings were categorised (according to the 
National Statistics Department, Colombia) as rural 
(indigenous or non-indigenous), or urban. Indigenous 
settings comprised those with Amerindian populations 
mostly following traditional lifestyles (Arhuaco, Bari, 
Hitnú, Kogui, Uwa and Wiwa communities).9 Seropreva-
lence data for those aged <1 year were excluded to avoid 
biases due to passive antibody transfer from mother to 
fetus. Each serosurvey was cross-validated to eliminate 
duplication of records. Details of the literature search 
are described in online supplementary data (text A) and 
online supplementary table 1 .
data analysis, catalytic models and FoI estimation
Descriptive prevalence results are reported as percent-
ages and accompanied by 95% binomial (exact―Clop-
per-Pearson) CIs (95% CI). For the FoI models, we 
consider that if the rate of infection acquisition―here 
the rate of seroconversion―is constant over time, 
infection (sero)prevalence will increase monotonically 
Key questions
What is already known about this topic?
WHO’s milestones for 2020 include elimination of intradomiciliary 
(vectorial) transmission of Chagas disease in endemic Latin American 
countries as well as provision of care to acute and chronically infected 
individuals. We sought to evaluate progress towards these aims 
illustrating our approach with Colombia. We did not identify recent 
studies modelling spatial and temporal trends in Chagas disease 
incidence (measured by the force-of-infection (FoI)) at national or 
subnational scale with the purpose of addressing the question of 
whether Colombia is on track to achieve the 2020 goals.
What are the new findings?
We find that in Colombia, the FoI has decreased in many locations 
probably due to interventions undertaken in the last three 
decades, but substantial heterogeneity remains at subnational and 
epidemiological setting levels. The FoI in Amerindian (indigenous) 
populations has remained essentially unchanged and can be 60 times 
as high as in urban settings, suggesting that no effective interventions 
have been implemented in the former. These heterogeneities indicate 
that achieving transmission interruption by 2020 is unlikely. In addition 
to this, even in areas with a marked reduction in incidence, we find a 
large remnant of prevalent cases in the adult population (exposed to 
higher FoI earlier in life), indicating that this age group bears most of 
the disease burden and is/will be in need of treatment and/or care.
recommendations for policy
We argue that FoI models fitted to seroprevalence data such as 
those applied here could be used to analyse retrospectively the 
many serosurveys already available in Latin America. This would 
allow quantification of incidence trends and determination of age-
specific prevalence for assessment of intradomiciliary transmission 
interruption. Greater efforts should be made in the region in terms of 
vector control and particularly in ensuring a systematic data collection 
of both surveillance and vector control activities to corroborate the 
finding from seroprevalence studies. This would greatly assist efforts 
towards Chagas disease prevention, control and care in the region.
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with age as cumulative exposure increases. Formally, 
Pa = 1− exp
(−λa), with Pa the age-specific seropreva-
lence and λ the FoI (the per susceptible incidence) as 
originally described by Muench.10 11 More generally, the 
FoI may fluctuate over time τ, modifying the seroprev-
alence age profiles. For a survey completed at time τ







.12 Therefore, a sero-
survey completed at time τ, and including ages a from {
amin, amax
}





 and τ. Other modelling assumptions 
included: (a) no age-dependency in transmission,12 (b) 
no seroreversion12 and (c) no specific migration due to 
Chagas infection status.12 13
Based on this, three catalytic models were compared:
Model 1: a model with constant FoI (λt = λ), as described 
above.11
 Pa = 1− exp
(−λ a) (1)
Model 2: a model with discrete change(s) in FoI. If 
a survey is conducted at time τ, and it is assumed that 
the FoI was constant (λ1) previous to time ξ1, but subse-
quently modified (to λ2), for example, due to an inter-
vention, remaining constant thereafter, the expected 
seroprevalence for an individual born before ξ1 would be,
 Pa,τ = 1− exp
(− [λ1 (a− (τ − ξ1)) + λ2 (τ − ξ1)]) (2)
and the expected seroprevalence for an individual born 
after ξ1 would be Pa,τ = 1− exp
(−λ2 a). In this case, ξ1 is 
also a parameter to be estimated. We considered up to 
four discrete changes in FoI (for estimation of up to five 
values of λ i and up to four values of ξi).
Model 3: a model with yearly variation in the FoI,








First, each model (1–3 above) was fitted to data from 
each of the 109 serosurveys to estimate the FoI and 
understand how best to explain incidence and prevalence 
patterns. Second, the same models were fitted to data 
aggregated at subnational (first administrative, depart-
ment-specific) level. As the Sierra Nevada de Santa Marta 
(SNSM) covers an extensive area (21 158 km2) belonging 
to three departments (Cesar, Guajira and Magdalena), 
yet encompassing unique epidemiological conditions not 
typical of the component departments,14 it was consid-
ered as a separate area for the subnational analysis. Third, 
setting-specific FoI was examined, allowing separate anal-
yses to be conducted according to rural indigenous, rural 
non-indigenous, urban and mixed settings.
Model fitting and comparison
We formulated a likelihood for each model containing 
the expected (predicted) prevalence according to equa-
tions 1–3 above (parameter dependent), assuming 
that observations follow a binomial distribution (text 
B of online supplementary data). For all three models, 
expected prevalence was adjusted to account for the 
sensitivity and specificity of the diagnostic test(s) used in 
each seroprevalence study (text C of online supplemen-
tary data). The parameters’ joint posterior distribution 
was obtained using Bayesian Markov Chain Monte Carlo 
sampling with the Metropolis-Hastings Algorithm,15 
implemented in R (V.3.2.2),16 assuming uninformative 
(flat) priors for all parameters and performing 1 00 000 
iterations. After discarding 20 000 initial burn-in itera-
tions and thinning to retain 1 in every 50 samples, the 
median and 95% Bayesian credible intervals (95% BCI) 
of the parameters were obtained. The deviance informa-
tion criterion (DIC) was used to compare the models, 
with a difference >10 units taken to indicate a significant 
difference in the goodness of fit to the data.17 When 
models had similar DIC values, the most parsimonious 
model (the one with the least number of parameters) 
was preferred. Spatial correlation between the values of 
FoI derived from the serological surveys (using model 3) 
was investigated by fitting semivariograms using the geoR 
package18 (see text D of online supplementary data).
ethics
This study was approved by the Ethics Committee of the 
National Institute of Health in Colombia (Code CTIN N° 
14–2011) under the principles embodied in the Declara-
tion of Helsinki.
results
The compiled dataset comprised 83 742 individuals from 
15 endemic departments who participated in 109 sero-
surveys from 1995 to 2014 (see online supplementary 
table 1). From those, seven serosurveys (in four commu-
nities) were of rural indigenous populations, 46 of rural 
non-indigenous, 33 of urban and 23 of mixed locations 
(see online supplementary figure 1). The geographical 
distribution of the serosurveys is presented in figure 1. 
Prevalence of Chagas infection varied markedly across 
departments, settings and age groups. The highest prev-
alence values were found among the indigenous commu-
nities (Arhuacos, Koguis and Wiwas) of the SNSM in 2000 
(47.1%; 95% CI 43.1% to 54.3%) and the Hitnú commu-
nity in 2012 (48.7%; 95% CI 42.6% to 51.6%). The lowest 
prevalence values were found in urban settings of Boyacá 
and Santander (see online supplementary table 1). All the 
FoI values given in the following sections are expressed 
per 1000 at-risk (susceptible) population per year.
FoI from individual serosurveys
The best-fit models for each individual serosurvey are 
presented in online supplementary table 2. A marked 
heterogeneity in the FoI was observed both temporally 
and geographically (figure 2 and online supplemen-
tary figure 2). The FoI was observed to vary between 
(subnational) administrative departments (figure 2A) 
and overall to decline with time (figure 2B) and from 
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Figure 1 Geographical distribution of serosurveys of Trypanosoma cruzi infection in Colombia. Locations are endemic 
departments (in green); size of the circles represents sample size; colours represent type of epidemiological setting; for 
departments in grey there are no available seroprevalence data. Inset shows location of Colombia in Latin America.
indigeneous to urban settings (figure 2C). The spatial 
analysis showed non-significant spatial correlation 
between the FoI values derived from individual serosur-
veys (see online supplementary figure 3).
The highest FoI values from individual serosurveys were 
identified for indigenous communities (figures 2 and 3). 
In the Hitnú communities, the FoI was 66 (95% BCI 52 to 
91) based on a 2012 survey. In the SNSM communities, the 
FoI was 30 (95% BCI 26 to 35), based on three different 
surveys (2000, 2007 and 2014). In the Uwa community, 
the FoI was also 30 (95% BCI 20 to 44), based on a 2009 
survey. For the Bari community in Santander Norte, a 
single intervention model (model 2) fitted the data best, 
suggesting that the FoI decreased from 14 (95% BCI 10 
to 22) before the late 1980s to 0.1 (95% BCI 0.005 to 1.4) 
afterwards. The average predicted prevalence by age 15 
years reached 60% in Hitnú, 36% in SNSM, 35% in Uwa 
and only 0.2% in Bari communities (figure 3).
subnational-level trends in FoI
Online supplementary Table 3 presents the best-fit 
model for each administrative department. Data and fits 
for Boyacá, Casanare and Santander, the departments 
providing most of the available information, are shown in 
figure 4. Boyacá and Santander have had significant reduc-
tions in FoI over time. For these departments, the FoI was 
currently estimated at <1 per 1000 population at-risk per 
year (figure 4A) and the predicted prevalence dropped 
sharply to <1% in children aged ≤15 years (figure 4B; 
expected prevalence for 2010). In Casanare, the FoI was 
historically somewhat lower than in Boyacá and Santander. 
Although a decreasing trend was also observed in this 
department, Casanare currently has one of the highest FoI 
values at departmental level, reaching 3 in 2013 (95% BCI 
2 to 4), that is, more than three times greater than those 
of Boyacá and Santander. In contrast, for departments 
such as Bolivar and Guainía, the FoI remained constant 
over time at a low level (<1), and the predicted age prev-
alence profiles differ markedly from those in traditionally 
endemic departments (see online supplementary figure 
2). Trends in the FoI at subnational level between 1990 and 
2014 are presented in figure 5. Note that for the depart-
ments in grey there were no seroprevalence data available.
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Figure 2 Geographical, temporal and setting-level heterogeneities in the force-of-infection (FoI) of Chagas disease in 
Colombia. (A) Averaged FoI from individual serosurveys for subnational (first administrative) level (departments) per 1000 
population at-risk per year. ANT, Antioquia; ARA, Arauca; BOL, Bolívar; CAS, Casanare; CES, Cesar; CUN, Cundinamarca; 
GUN, Guainía; MAG, Magdalena; MET, Meta; NST, Norte Santander; SAN, Santander; SNSM, Sierra Nevada de Santa 
Marta; SUC, Sucre; TOL, Tolima. The location of the departments has been provided in figure 1. (B) Averaged (overall) FoI 
by quinquennial period. (C) Averaged FoI by quinquennial period and type of setting (rural indigenous, mixed, rural-non-
indigenous and urban). Bottom and top of the box are first and third quartiles; the horizontal band inside is the median; the 
whiskers are the minimum and maximum 1.5 IQR and the solid circles are the outlier values.
setting-level trends in FoI
When the information was analysed separately by indige-
nous, rural (non-indigenous) and urban settings, marked 
differences were observed in FoI trends, reflecting 
distinct epidemiological conditions.
Rural indigenous settings
For the four indigenous groups, a constant FoI fitted 
best (model 1, online supplementary table 4), with an 
average FoI of 20 (95% BCI 18 to 22) (figure 6A, upper 
left panel). Age-prevalence profiles for the years 2000 
and 2010 are shown in figure 6B, lower left panel).
Rural (non-indigenous) settings
A model with yearly changes in FoI (model 3) was 
preferred in rural communities, based on 46 serosurveys 
from 15 Chagas-endemic departments (see online supple-
mentary table 4). In the early 1990s, the FoI reached 
up to 10 (95% BCI 8.3 to 11.9), decreasing thereafter. 
From 1999 onwards, the median FoI was estimated at 0.9 
(0.1–2.2) (figure 6A, upper middle panel). In 2010, the 
predicted prevalence in those aged ≤5 years was <3%, 
reaching 20% (95% BCI 18% to 23%) among those aged 
25 years and increasing to 44% (40%–50%) among those 
aged 60 years (figure 6B, lower middle panel).
Urban settings
Two changes in the FoI were inferred in 1995 and 2002 
(model 2, online supplementary table 4) from a total of 
33 serosurveys in Arauca, Boyacá, Casanare, Santander 
Norte and Santander. The FoI was 5.6 (95% BCI 4.2 to 
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Figure 3 Force-of-infection (FoI) and prevalence trends of Chagas disease in four different indigenous settings in 
Colombia. (A) FoI per 1000 population at-risk per year vs year for the period 1984–2014. Red solid lines represent median 
FoI and pink shaded areas the 95% Bayesian Credible Intervals (95% BCI) according to best-fit models. (B) Age profiles 
of Chagas disease seroprevalence in specific years. Blue solid lines represent median predicted prevalence and coloured 
shaded areas the 95% BCI; solid circles represent observed prevalence values (plotted for the midpoint of each 10 year age 
range) and error bars are exact 95% CI. Panels from left to right correspond to four different indigenous groups, namely, Bari 
(Santander Norte) in 2012, Hitnu (Arauca) in 2012, Uwa (Boyacá) in 2009 and Sierra Nevada de Santa Marta (SNSM*, two 
serosurveys in 2007–2014).
8.1) before 1990, 0.8 (95% BCI 0.4 to 1.6) until 2002 
and 0.02 (95% BCI 0.0004 to 0.2) from 2003 onwards 
(figure 6A, upper right panel). Predicted seropreva-
lences were lower than those in rural areas, yet >5% of 
adults aged 30 years were predicted to be seropositive, 
with prevalence reaching 19% (95% BCI 15% to 25%) 
among those aged 60 years (figure 6B, lower right panel).
dIscussIon
Although progress has been made in Latin America 
towards Chagas disease control, within-country hetero-
geneities in transmission intensity, incidence and prev-
alence remain poorly recognised and quantified. Here, 
we used detailed retrospective analyses of seroprevalence 
data to quantify such temporal and spatial heterogenei-
ties in Colombia. The estimated FoI of Trypanosoma cruzi 
(as measured by the force-of-seroconversion) in several 
endemic rural and urban areas of Colombia showed a 
reduction over the last three decades (eg, by nearly 90% 
in some areas of Boyacá and Santander), likely due to 
reductions in intradomiciliary transmission. However, 
high FoI persists in some areas, particularly in remote 
rural and indigenous settings (where the FoI can be up 
to 80 times greater than in non-indigenous populations 
of the same administrative units, eg, compare serosurveys 
75–77 in online supplementary figure 2). Importantly, 
our results also reveal a large remnant of prevalent cases 
(and hence burden of disease) in adult populations 
throughout Colombian endemic regions due to high 
exposure earlier in life.
The fitted models provided reasonable predictions of 
seroprevalence age profiles across the surveys examined. 
The outputs for Boyacá and Santander are consistent 
with the recent recognition of local interruption of intra-
domiciliary transmission in some municipalities of these 
departments, particularly those previously infested by 
intradomiciliary R. prolixus.19 However, such reductions 
in transmission were not experienced in all departments, 
for example, the estimated FoI for Casanare was at least 
three times greater than those of rural areas of Boyacá 
and Santander. The presence of active sylvatic transmis-
sion by R. prolixus, whose distribution is expanding due to 
landscape transformation in the region, is likely to play 
a role as this species is less well tackled by more tradi-
tional vector control strategies. Numerous studies have 
illustrated the difficulties in controlling sylvatic triato-
mine populations, including (1) lower effectiveness of 
insecticide spraying strategies and higher risk of triato-
mine recolonisation of dwellings,12 18 20 and (2) occur-
rence of oral transmission outbreaks.21 In line with this 
observation, the low and atypical (weakly age-related) 
seroprevalence profiles observed in some endemic areas 
of Antioquia and Bolivar—where no clear history of 
domiciliary transmission exists22 —may also be due to 
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Figure 4 Temporal trends in the force-of-infection (FoI) and age-prevalence profiles of Chagas disease in Colombia at 
subnational level in three of the most endemic departments. (A) FoI per 1000 population at-risk per year vs year for the period 
1984–2014. Red solid lines represent median FoI and pink shaded areas the 95% Bayesian Credible Intervals (95% BCI) 
according to best-fit models. (B) Age profiles of Chagas disease seroprevalence for 2000 (green) and 2010 (blue). Coloured 
solid lines represent median predicted prevalence and coloured shaded areas the 95% BCI; solid circles represent observed 
prevalence values (plotted for the midpoint of each 5-year age range) and error bars are exact 95% CI. Panels from left to 
right correspond to Boyacá (model 2), Casanare (model 3) and Santander (model 3).
sylvatic and oral transmission by secondary vectors such 
as Rhodnius pallescens or Panstrongylus geniculatus.23–27 
Finally, the observed incidence trends in urban settings 
are likely to reflect migration from rural areas to towns 
and cities, as such settings are deemed unlikely to sustain 
active vectorial transmission. Although the magnitude 
of rural to urban migration has been well documented 
(from 70% of the Colombian population living in rural 
areas during the 1940s to 30% currently),28 the role of 
population movement in shaping the epidemiology of 
Chagas disease in endemic countries is still poorly under-
stood.29 30
Serology, as a diagnostic technique for Chagas disease, 
has a number of limitations (particularly for detecting 
the acute phase), including problems of interpretation as 
a direct marker of infection, unknown relationship with 
disease progression and cure and not well-understood 
rates of seroreversion.6 31 Although the diagnosis of T. cruzi 
infection has improved in recent years, especially with 
the development of PCR-based molecular techniques, 
their limited sensitivity in the chronic phase (57%–64%) 
and high cost have confined their use to specialised 
laboratories and prevented their field testing to replace 
traditional serology.32 Therefore, and despite its limita-
tions, seroprevalence surveys remain relevant, affordable 
and relatively easy to implement in endemic settings, 
permitting the assessment of transmission patterns and 
trends, as demonstrated in other studies.11 32–34 However, 
since different serodiagnostic assays differ in their sensi-
tivity and specificity, it will be crucial to adjust estimates 
according to the diagnostic performance of the tests used 
in the various serosurveys (as implemented in this study).
In Peru and Bolivia, catalytic models based on serolog-
ical surveys conducted at small scales (eg, within a city), 
allowed identification of specific years when interrup-
tion of T. cruzi transmission was achieved,33 assessment 
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Figure 5 Maps illustrating spatiotemporal changes in force-of-infection (FoI) of Chagas disease in Colombia (1990–
2014). Colour intensity represents the magnitude of the FoI (per 1000 population at-risk per year); for departments in grey 
there are no available seroprevalence data. The identification of the departments has been provided in figure 1.
of the impact of reinvasion by triatomines once vector 
control was stopped34 and characterisation of local intro-
duction and spread at fine spatial scales, helping to iden-
tify microepidemics.35 Using aggregate data at a national 
scale, Feliciangeli et al showed the potential of FoI models 
to understand Chagas disease trends in Venezuela from 
1940 to 2000.12
While an aggregate approach at a national level has 
the advantage of providing a broader picture, it has the 
disadvantage of potentially masking important under-
lying heterogeneities that need to be highlighted. We 
attempted to bridge the gap between microepidemiolog-
ical and macroepidemiological scales by analysing 109 
serosurveys individually and subsequently aggregating 
them at subnational and setting scales. In doing so, we 
acknowledge a risk of observing survey-specific hetero-
geneities rather than true underlying temporal and/
or spatial patterns on the one hand, and on the other 
assuming homogeneity within administrative units or 
settings. We did not, however, aggregate the data at a 
national level, as this could lead to erroneous conclu-
sions regarding the impact of Chagas disease control in 
Colombia. Besides, there are still areas of the country 
where seroprevalence studies have not been conducted or 
are not yet available. Ideally, surveys should be conducted 
not by simple random sampling, but by adaptive sampling 
methods36 in endemic areas, including those where infor-
mation is still lacking.
Previous studies have informed that the main vector 
of Chagas disease in Colombia, R. prolixus, has restricted 
its geographical distribution in recent years, possibly 
due to control actions (insecticide spraying, education 
programmes) mainly carried out by the secretaries of 
health of the departments of Boyacá, Cundinamarca 
and Santander; along with a reported expansion of the 
same species’ distribution across the oriental plains of 
the country (departments of Casanare and Meta partic-
ularly), where palms cultures have been extended 
and sylvatic transmission takes place.37 Interestingly, 
as R. prolixus is mostly a so-called introduced species 
across the Andean region in Colombia, this has a much 
greater potential to be eliminated (and interruption 
transmission achieved after basic control strategies) 
that in comparison with the oriental plains region or 
even Venezuela, where R. prolixus is mostly considered 
an autochthonous species.38 Unfortunately, detailed 
data about specific control interventions undertaken 
in the different locations across the three decades 
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Figure 6 Temporal trends in force-of-infection (FoI) and age-prevalence profiles of Chagas disease in Colombia at setting 
level. (A) FoI per 1000 population at-risk per year vs year for the period 1984–2014. Red solid lines represent median FoI and 
pink shaded areas the 95% Bayesian Credible Intervals (95% BCI) according to best-fit models. (B) Age profiles of Chagas 
disease seroprevalence for 2000 (green) and 2010 (blue). Coloured solid lines represent median predicted prevalence and 
correspondingly coloured shaded areas the 95% BCI; solid circles represent observed prevalence values (plotted for the 
midpoint of each 5-year age range) and error bars are exact 95% CI. Left, centre and right panels correspond, respectively, to 
indigenous (model 1), rural non-indigenous (model 3) and urban (model 2) settings.
investigated in this paper are scarce, non-centralised 
and therefore not available in public repositories nor 
through the Ministry of Health. On the other hand, 
major changes in terms of housing living conditions in 
some rural areas of the country have also been resulted 
from housing improvement programmes in the last 
three decades.28 Indeed, two recent seroprevalence 
studies in different locations have shown that adults in 
Chagas endemic areas used to live in poorer housing 
conditions two decades ago (ie, 40%–47% exposed to 
soil floor in childhood vs 9%–12% in present days39 40). 
We hypothesise that these structural changes could also 
potentially play a role towards the reduction of domi-
ciliary transmission in some locations identified in this 
study. Such information on vector control surveillance 
and socioeconomic conditions would certainly help 
confirm and explain the findings of this research and 
further investigate the underlying causes of historical 
changes in the FoI and to assess the real potential for 
sustained elimination.
conclusIon
FoI models such as those applied here could be used to 
analyse retrospectively many of the serosurveys already 
available in Latin America to quantify incidence trends 
and obtain age-specific prevalence profiles that would 
allow assessment of whether serological (or other) 
criteria for intradomiciliary transmission interrup-
tion have been met. Such a relatively low-cost exercise 
(compared with the collection of longitudinal data), 
could help endemic countries to quantify the impact of 
(historical and/or current) interventions, estimate the 
number of prevalent cases and ensuing disease burden, 
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conduct cost-effectiveness and economic evaluations41 
and ultimately assess whether they are on track to reach 
the WHO 2020 goals. Despite the evident progress in 
some regions, given the marked heterogeneity in the 
FoI found in this research, between rural and urban 
areas and between indigenous and non-indigenous 
settings, it is unlikely that the goal of achieving interrup-
tion of domiciliary transmission in all endemic areas of 
Colombia can be met by 2020. Greater efforts should be 
made in terms of improving vector surveillance, detailed 
records of interventions undertaken and conducting 
seroprevalence studies, especially in areas where there is 
not recent information available. Also, given the results 
of this research, for future serosurveys in Latin America, 
it would be advisable to include socioeconomic varia-
bles in adaptive sampling designs, and ideally should be 
conducted with representativeness at subnational level, 
especially when transmission interruption is under evalu-
ation. This would greatly assist endemic countries’ efforts 
towards Chagas disease prevention, control and care in 
the region.
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